CH - HIV/Aids

HIV infected and developed one or more of certain clinical conditions

fungal infection (7%)

parasidic pneumonia (34%)

rare skin cancer (15%)

T (white blood) cells that fight infections are in low number (avg 1000-1200)

1.2 million

900,000

300,000

35,000 (Peak 50,000)

40 million

Men intercourse with other Men

Drug Use

Heterosexual contact

Combo of Drug use and homosexual intercourse

Blood Transfusion

Black, White, Hispanic, Asian, American Indian

New York (220,000)

California (180,000)

Florida (100,000)

Texas (100,000)

New Jersey (60,000)

New York (220,000)

Los Angeles (65,000) (Hollywood Wilshire District)

San Francisco (50,000)

Washington DC (45,000)

Miami (36,000)

acts opposite of a normal virus. It copies itself in a Host (T-cell) through the process of reverse transcription

1. Acute HIV infection, 2. Chronic HIV Infection 3. Aids

HIV then copies itself and infects the other T-cells within the body quickly dropping numbers from 1200 to 200

Direct Exchange of Bodily fluids, Intravenus Drug needle/syringe, Perinatal transmission from mother to fetus, Blood Supply

Blood, Semen, Vaginal Secretions, Mother’s milk

20 times stronger than vaginal secretions in spreading HIV

1-3 weeks

2-6 months

Depends on the health of the person and their immune system (1 year to never, avg 11 years to aids)

45%

25% Men (40% women)

17% Men 55% Women in US (75% world)

less than 2% in the Us ( less than 5% in the world)

Detecks HIV from B cells; if positive Western Blot test will confirm

Detects HIV Antibodies in Saliva

Pre exposure prophylaxis drug treatment for those at high risk for HIV infection

After potential exposure antiviral drug treatment following a single high risk event (within 3 days)

Combo of antiviral drugs that attack an enzyme (HIV protease) necessary for HIV to copy itself

Dozens of pills taken daily at precise time

skins, mucous membranes, tears, earwax, saliva, cilia

white blood cells that produce antibodies

White Blood cells that attack fungi, parasites, viruses and cancers

Protected in future due to previous exposure

antibodies developed from killed or weak virus

Antibodies from outside source